Promising vaccines in the fight against mpox
This issue of our newsletter is supported by Inpart.
The World Health Organization (WHO) has declared a global public health emergency as the mpox virus ravages the African continent with cases having spiked by 160% this year.
The only marketed mpox vaccine is Bavarian Nordic’s Jynneos, which was approved for emergency use by the FDA in 2022 when another mpox outbreak occurred.
However, countries suffered Jynneos shortages that year, leaving a need for more vaccines to be developed and produced.
Currently, GeoVax is in the running to have its MVA vaccine approved for mpox, and Moderna is currently trialling an mpox vaccine in the UK.
To find out more, read the full article: “Fighting mpox: promising vaccines to watch”
A MESSAGE FROM OUR SPONSOR INPART
Respiratory health R&D trends and breakthrough innovations
Copy: Download a copy of Inpart’s new report surfacing exclusive insights in respiratory heath R&D, and connect with teams developing breakthrough innovations, including vaccine candidates for emerging infectious diseases and first-in-class anti-fibrotics.
🔥 More noteworthy articles from this week:
CAR-T therapy has been linked to serious side effects, following which U.S. regulators issued boxed warnings on the treatment. Now, growing concerns over parkinsonism – a condition characterized by a range of movement symptoms like tremors and muscle rigidity – have led to a clinical trial halt for Belgian pharmaceutical Galapagos’ candidate.
Developing treatments for neurological diseases presents a huge challenge for neuroscience companies within the biotech industry. These challenges have even led to big pharma companies shutting down their neuroscience drug development programs. Fortunately, plenty of smaller biotechs have kept research in this area alive – here, we take a look at 10 of the top neuroscience companies around today.
Currently, many companies are concerned about fundraising, but there are things that can be done to maximize efforts. To look at questions surrounding the state of European biotech funding, and how it compares with the global scene, intellectual property, and how to challenge the status quo, we have a conversation with Dima Kuzmin, managing partner at 4BIO Capital.
Microbial expression systems are widely used to manufacture diagnostic and therapeutic proteins, with insulin being the best-known example. However, the commercialization success rate for new drug developments is less than 3%, partly due to high development and manufacturing costs, long turnaround times, and challenging product safety profiles.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.